Scientific publisher Thieme Chemistry has announced that 'Pharmaceutical Substances' version 3.8 is now available. This substantial new release for the reference guide includes 31 new active pharmaceutical ingredients such as Ledipasvir, that combined with Sofosbuvir allows for the first all-oral treatment of Hepatitis C infections.
The new release contains 31 new active pharmaceutical ingredients (APIs), which have been approved recently by the Food and Drug Administration (FDA) and/or the European Medicines Agency.
Professor B. Kutscher, along with renowned scientists Professors A. Kleemann and J. Engel and Dr. D. Reichert compiled this influential reference guide. It contains syntheses, patents and applications of nearly 2.600 active pharmaceutical ingredients including intermediates. According to Professor B. Kutscher, this spring release includes a lot of first-in-class drug products that have innovative mechanisms of action as well as anticipated blockbuster potential. Breakthrough therapy designation was received by the two new APIs Nintedanib and Pirfenidone against the challenging indication Idiopathic Pulmonary Fibrosis (IPF) for example. Peramivir is the first injectable neuraminidase inhibitor against influenza. Additionally, monographs for the new kinase inhibitors Palbociclib, Olaparib and Idelalisib were added.
'Pharmaceutical Substances' is projected as an invaluable resource for researchers, process chemists teaching in the field of medicinal and pharmaceutical chemistry and everyone involved in the design, discovery, development and evaluation of drugs. It is a first point of reference for any person wishing to screen references to drugs before turning to more detailed primary literature. Extensive indexing and cross linking of references provides the user with a fast and easy way to compare pharmaceutical ingredients with similar characteristics. Institutional access is granted after purchasing an annual license, prices depending on the number of potential users.
